Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease
BEVERLY, MA – Jan. 17, 2017 (GLOBE NEWSWIRE) Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to announce that enrollment has been completed in the second cohort of the Phase 2 open label Proof-of-Concept trial evaluating Brilacidin as a new treatment for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease.
In the trial, patients in the second cohort are being administered 100 mg of Brilacidin once daily as a retention enema for 42 consecutive days. As such, Cellceutix expects treatment of the second cohort to be completed by the end of February.
Initial data from the first cohort, treated with 50 mg Brilacidin once daily showed the drug to be well-tolerated, with no measurable systemic absorption detected. Clinically meaningful improvements in symptoms were documented through endoscopic evaluation, as well as physician assessments and patient reported outcomes.
“To date, the trial has exceeded our expectations on all fronts. The study needs to be successfully completed with the final data fully analyzed, but at this point we attribute the early favorable results to Brilacidin’s robust anti-inflammatory therapeutic profile. Given Brilacidin’s unique mechanism of action, the body is able to get back to doing what it’s usually already good at—fighting illness and infection,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix.
Leo Ehrlich, Chief Executive Officer at Cellceutix commented, “We raised a lot of eyebrows at meetings at the Biotech Showcase conference last week and are capturing the attention of Big Pharma with preliminary reports and scopes. Seeing the before and after endoscopic videos from patients in Cohort 1 is the most encouraging support of Brilacidin’s potential for treating IBD. I am proud to say that to date, every patient in this trial has benefited from their Brilacidin treatment.”
BEVERLY, MA – Jan. 17, 2017 (GLOBE NEWSWIRE) Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to announce that enrollment has been completed in the second cohort of the Phase 2 open label Proof-of-Concept trial evaluating Brilacidin as a new treatment for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease.
In the trial, patients in the second cohort are being administered 100 mg of Brilacidin once daily as a retention enema for 42 consecutive days. As such, Cellceutix expects treatment of the second cohort to be completed by the end of February.
Initial data from the first cohort, treated with 50 mg Brilacidin once daily showed the drug to be well-tolerated, with no measurable systemic absorption detected. Clinically meaningful improvements in symptoms were documented through endoscopic evaluation, as well as physician assessments and patient reported outcomes.
“To date, the trial has exceeded our expectations on all fronts. The study needs to be successfully completed with the final data fully analyzed, but at this point we attribute the early favorable results to Brilacidin’s robust anti-inflammatory therapeutic profile. Given Brilacidin’s unique mechanism of action, the body is able to get back to doing what it’s usually already good at—fighting illness and infection,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix.
Leo Ehrlich, Chief Executive Officer at Cellceutix commented, “We raised a lot of eyebrows at meetings at the Biotech Showcase conference last week and are capturing the attention of Big Pharma with preliminary reports and scopes. Seeing the before and after endoscopic videos from patients in Cohort 1 is the most encouraging support of Brilacidin’s potential for treating IBD. I am proud to say that to date, every patient in this trial has benefited from their Brilacidin treatment.”
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All content of my posts is my opinion and speculation. Do not treat anything I say as fact or actionable investment advice. I participate to challenge my investment thesis from any angle possible. Please do your own due diligence.
Current Positions:
Long CTIX.
Current Positions:
Long CTIX.
